Clinical Trial Update: Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pembrolizumab in combination with olaparib for advanced BRCA-mutated or homologous recombination deficiency breast cancer has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• Lynparza (olaparib)

Snippet

Sponsor: Yuan Yuan | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2025-05-29